{"created":"2023-05-15T14:51:45.357889+00:00","id":70750,"links":{},"metadata":{"_buckets":{"deposit":"f6034af2-9a53-4218-9ebc-74c47e3363ac"},"_deposit":{"created_by":1,"id":"70750","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"70750"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00070750","sets":["10:28"]},"author_link":["695012","695009","695011","695013","695017","695008","695014","695006","695010","695016","695007","695015"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2012-05-13","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Purpose/Objective\nThe aim of this study was to evaluate the role of positron emission tomography using 18F-fluorodeoxyglucose (FDG-PET) in the indication of preoperative carbon ion radiotherapy for the patients with resectable pancreatic cancer.\nMaterials and Methods\nThe patients with resectable pancreatic cancer underwent preoperative short course carbon ion radiotherapy (CIRT) in our institution. On the PET-CT before CIRT, the tumor was contoured and the maximum standardized uptake value (SUVmax) was calculated. The SUVmax was compared between two groups, patients with and without distant recurrence after CIRT. The low-SUVmax and the high-SUVmax subgroups were created by categorizing patients above or below the median SUVmax. The impact of the SUVmax on the prognosis for patients was assessed by analyzing the correlations between the SUVmax and the distant metastasis free survival (DMFS) and overall survival (OS). In addition, the analysis was performed by following factors; age, carbohydrate antigen 19-9, tumor volume, and clinical stage.\nResults\nTwenty-one patients were included in this study. Sixteen of 21 patients underwent surgery. For the entire population, local recurrence was observed in no patient and distant metastasis in 13 patients (62%). The median SUVmax was 4.3 (range, 2.2-8.2). DMFS of the low-SUVmax group and the high- SUVmax group were 91% and 20% for 1 year and 71% and 0% for 3 year, respectively (p<0.0001). OS of the low-SUVmax group and the high-SUVmax group were 91% and50% for 1 year and 81% and 0% for 3 year, respectively (p<0.0001). An SUVmax >4.3 was the only risk factor for distant recurrence in the univariate analysis.\nConclusions\nOur data indicated statistically significant correlation between SUVmax and DMFS. FDG-PET is considered to be useful to determine the indication of preoperative short course CIRT for the patients with resectable pancreatic cancer.","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"ESTRO 31","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Shinoto, Makoto"}],"nameIdentifiers":[{"nameIdentifier":"695006","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yamada, Shigeru"}],"nameIdentifiers":[{"nameIdentifier":"695007","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yoshikawa, Kyosan"}],"nameIdentifiers":[{"nameIdentifier":"695008","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yasuda, Shigeo"}],"nameIdentifiers":[{"nameIdentifier":"695009","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Imada, Hiroshi"}],"nameIdentifiers":[{"nameIdentifier":"695010","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kamada, Tadashi"}],"nameIdentifiers":[{"nameIdentifier":"695011","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"篠藤 誠","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"695012","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"山田 滋","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"695013","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"吉川 京燦","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"695014","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"安田 茂雄","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"695015","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"今田 浩史","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"695016","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"鎌田 正","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"695017","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"Role of FDG-PET as a predictor of distant failure in preoperative Carbon-ion radiotherapy for pancreatic cancer","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Role of FDG-PET as a predictor of distant failure in preoperative Carbon-ion radiotherapy for pancreatic cancer"}]},"item_type_id":"10005","owner":"1","path":["28"],"pubdate":{"attribute_name":"公開日","attribute_value":"2012-05-21"},"publish_date":"2012-05-21","publish_status":"0","recid":"70750","relation_version_is_last":true,"title":["Role of FDG-PET as a predictor of distant failure in preoperative Carbon-ion radiotherapy for pancreatic cancer"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T19:59:16.032565+00:00"}